Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
The identification of these mutations in patients with advanced NSCLC can provide them with the opportunity to receive optimal targeted therapies, known as Tyrosine Kinase Inhibitors (TKIs). In
"At the time of recurrence or progression of non-small cell lung cancer, many patients may not have the option to have an assessment of EGFR mutation status because all of the original tissue biopsy material was consumed by the diagnostic testing conducted to identify the cancer. In other cases, patients may be too sick to undergo a surgical biopsy. For patient populations who are not candidates for tissue biopsy, there is a clear need for a test that enables physicians to better manage their cancer," said
"With existing
Lung cancer is the leading cause of cancer-related death among men and women. According to data from the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to improvement of outcomes, our impact on diagnostic strategies and planned future offerings, such
statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Reference
http://www.nejm.org/doi/full/10.1056/NEJMoa1406766
CONTACT: Investor Contact:Source:The Ruth Group David Burke (646) 536-7009 dburke@theruthgroup.com Media Contact:The Ruth Group Melanie Sollid-Penton (646) 536-7023 msollid@theruthgroup.com
News Provided by Acquire Media